⛵Dhow Dispatch │ Amano Labs - The $20 Hearing Aid Question

Before diving in: Dhow Horizon Fund I is now live.

Our first product offering is Dhow Horizon Fund I, a $5M seed-stage venture fund backing Muslim-origin and values-aligned technology founders across North America.

Our thesis is simple: exceptional founders from our community are already building in massive markets, but they remain underfunded by traditional VC and underconnected to aligned capital. Through Dhow’s founder, investor, and community network, Horizon has access to 200+ on-thesis companies that have collectively raised $6B+ in verified funding, giving us a differentiated sourcing advantage before many of these companies become obvious to the broader market.

That advantage is already showing up in the pipeline. One promising founder is currently holding allocation for us in a fast-growing consumer AI company with the kind of early traction most seed companies never touch: a six-figure waitlist, massive organic reach, thousands of beta users, unusually strong engagement, proprietary consumer data, and early B2B pull from major media and entertainment players. We’re keeping the company private for now, but it’s exactly the kind of deal we’d like to move on quickly.

We’re preparing for our first close and gearing up to begin deploying capital in June. If you’re an accredited investor interested in backing overlooked Muslim-origin and values-aligned founders early, reply “Horizon” and we’ll send over the deck.

You can also submit a soft commitment here

🚀 | TL;DR

Amano Labs is fascinating because it doesn’t feel like a typical consumer hardware startup. It honestly looks more like a group of young technical founders going directly after a healthcare category that’s been expensive and stagnant for years; this feels truer to the roots of a disruptive, industry changing startup than many of the more high-profile AI companies.

The company was founded by McMaster University students building around a simple idea: hearing care should not require devices that cost thousands of dollars. Amano describes itself as focused on accessible, personalized hearing technology, with the venture growing out of McMaster University and informal research connections at Harvard Medical School and St. Joseph's Healthcare Hamilton.

The founding team includes Arish Shahab, Aaron Yu, and Ramin Syed, with the company currently testing iterations internally and actively recruiting audiologists, ENT practices, and users to participate in upcoming pilot deployments. That matters because hearing aids sit in an awkward space between consumer hardware, medical devices, and behavioral products. You really need all three pieces to work.

What makes Amano stand out is the approach: instead of building a slightly cheaper version of a traditional hearing aid, the team is experimenting with ultra-low-cost, 3D-printed amplification devices paired with machine-learning-based sizing and built-in output constraints for safety. The goal seems less about recreating premium hearing aids and more about making basic hearing assistance dramatically more accessible.

That’s also why the company spread so quickly online. A $19.99 sound amplification device in a category where regulated hearing aids regularly cost thousands is immediately understandable, even to people who know nothing about hearing care. (Note: Amano's founders describe the product as a 'sound amplification device' and 'bridge to clinical care' rather than a regulated hearing aid, and the company does not appear to be FDA-registered as an OTC hearing aid or licensed by Health Canada as of publication.) The real question now is whether Amano can turn that attention into a product that’s clinically useful, trusted, and scalable.

Founded: Founded: 2024 (student team); publicly launched May 2026
Founders: Arish Shahab, Aaron Yu, Ramin Syed
Sector: Hearing technology / consumer health
Product: Low-cost AI-assisted hearing aid
Price Point: ~$19.99 pre-order pricing
Focus: Affordable hearing assistance for mild-to-moderate hearing loss

Amano Labs is building a low-cost hearing aid designed to lower the barrier to basic hearing assistance. The company combines 3D-printed hardware, mechanical sound amplification, and machine-learning-assisted fitting into a product that aims to reduce the cost and complexity typically associated with hearing care. It's worth flagging the physics here: purely passive, 3D-printed acoustic amplification typically tops out around 10–20 dB of gain in narrow frequency bands, compared to the 30–60 dB of programmable gain delivered by digital hearing aids. That means Amano's approach is plausibly useful for the milder end of mild-to-moderate hearing loss but is unlikely to cover the full range that prescription or OTC digital aids address.

At a high level, the pitch is pretty straightforward: Traditional hearing aids average roughly $2,700 per pair across all U.S. purchase channels and still run close to $4,700 per pair at traditional clinics for uninsured private-pay buyers, often require clinical visits, and remain inaccessible for a large portion of people with hearing loss. Amano is trying to compress that process into something cheaper, easier to access, and simple enough to distribute more broadly.

The company appears focused primarily on mild-to-moderate hearing loss, which is important because that’s the segment opened up by the FDA’s over-the-counter hearing aid framework in recent years. Instead of competing directly with premium clinical hearing systems, Amano seems to be targeting the much larger group of people who either delay treatment entirely or never enter the system because of cost and friction.

That positioning matters more than you’d think. Hearing loss is a massive global market, but adoption rates remain surprisingly low relative to how common the problem actually is. Amano’s thesis seems to be that accessibility and simplicity, not just technology, are the biggest unlocks in the category.

The interesting thing about hearing aids is that the technology itself is not new. The problem has mostly been everything around it.

For years, hearing care has been tied to a system that’s expensive, clinical, and difficult to navigate. A lot of people who need hearing assistance never actually get it, either because the devices cost too much, the process feels intimidating, or the problem doesn’t feel “serious enough” to justify spending thousands of dollars.

That last part matters more than people realize. A huge portion of hearing loss is mild to moderate, which means many users spend years delaying treatment, even when it’s already affecting conversations, work, or daily life.

The FDA’s over-the-counter hearing aid ruling in 2022 was supposed to help address that by opening the door for adults with perceived mild-to-moderate hearing loss to buy hearing aids without a prescription or audiologist visit. The idea was to lower friction, increase competition, and generally bring prices down. But even after the rule change, most products in the category still sit hundreds or thousands of dollars above what many consumers are comfortable paying. That leaves ample room for companies approaching the market differently.

That’s where Amano gets interesting. The company’s core idea is not necessarily that hearing technology needs to become radically more advanced. Instead, it’s that hearing assistance may need to become radically simpler, cheaper, and easier to access before adoption meaningfully changes.

What Amano is building looks pretty different from a traditional hearing aid. While most modern hearing aids rely on expensive digital signal processing, custom fitting, proprietary chips, and clinical tuning, Amano appears to be taking a much lighter approach, combining mechanical amplification, 3D-printed hardware, and machine-learning-assisted fitting into a simpler system designed around affordability first.

The company has referenced AI-assisted sizing and personalization, which seems aimed at helping users find a better fit without going through the traditional audiology workflow. That’s an important detail because fit and comfort matter a lot in hearing devices. Even strong audio performance does not help much if people stop wearing the product.

Another interesting part of the approach is the focus on output constraints and safety limits. One of the real risks with low-cost amplification devices is over-amplifying sound and potentially making hearing damage worse. Amano appears aware of that problem and is designing around it early.

What’s still unclear is how much of the product behaves like a true hearing aid versus a simplified amplification device. That distinction matters both technically and regulatorily. Premium hearing aids do far more than increase volume, they filter background noise, isolate speech, adapt dynamically to environments, all while personalizing output in real time.

Amano seems to be making a different argument. For a large percentage of people with mild-to-moderate hearing loss, a simpler and dramatically cheaper product may be “good enough” to unlock adoption where nothing existed before. That’s a very different bet than trying to compete head-on with high-end medical hearing systems coming from incumbents in the space.

What makes Amano interesting is that the company seems to understand the true bottleneck in hearing care. For a lot of people, the issue is less about whether premium hearing technology exists and more about that the category has become too expensive, too clinical, and too intimidating for basic adoption. Amano is betting that lowering those barriers matters more than building the most advanced device on the market.

The price point is obviously a huge part of the story. A $20 product in a category where devices often cost thousands immediately changes who can realistically consider buying one. Even if the product ends up serving a narrower segment of users, the market for that segment is still enormous.

There’s also something important about how the company packaged the idea. The product is easy to understand in a single sentence, which sounds simple, but matters a lot for consumer adoption and distribution. People instantly understand why a low-cost hearing aid could matter.

The broader timing helps too. AI-native healthcare startups are increasingly being built around accessibility and workflow reduction. Amano fits into that shift naturally by focusing on lowering enough friction for more people to actually enter the hearing care system. If the product works well enough for a meaningful percentage of users, that alone could be a very large business.

The biggest question is whether the product actually works well enough in the real world. Going viral is one thing, however building a hearing device people trust enough to wear consistently is something completely different. Hearing products sit in a category where comfort, reliability, and user experience matter just as much as the core technology.

There’s also a real regulatory layer here. The FDA’s OTC hearing aid framework created a path for products like this, but low-cost hearing devices still need to operate within safety standards around amplification, labeling, and intended use. If Amano gains meaningful traction, the company will likely face much more scrutiny around performance claims and clinical validation.

Another open question is how durable the technology advantage actually is. If the core insight is primarily around affordability and distribution, larger incumbents could eventually move downmarket as well. That means Amano may need to win through brand, accessibility, speed, and user adoption rather than purely technical defensibility.

Retention is another thing worth watching closely. A lot of consumer health products generate initial curiosity, especially when the price point is low, but long-term usage is what matters. Hearing devices only become meaningful businesses if users continue wearing them consistently over time.

And then there’s the broader question underneath all of this. How much hearing assistance is “good enough” for the average user? Amano’s thesis seems to be that millions of people do not necessarily need premium clinical-grade systems, they just need something affordable and functional enough to improve day-to-day life. If that assumption is right, the market could be much larger than people think. If not, they face an uphill battle to gain meaningful market share.

Amano is interesting because it reflects a broader shift happening across healthcare and consumer technology at the same time. For a long time, healthcare innovation mostly moved upstream and looked like better hospitals, better clinical tools, and better specialist systems. What’s happening now is that a lot of startups are starting to move downstream instead, focusing on accessibility, simplicity, and distribution.

That changes the type of companies that can get built. Small teams can now take categories that were historically expensive or highly specialized and rethink them from the ground up using cheaper manufacturing, AI-assisted workflows, and direct distribution. The result is products that may not fully replace premium systems, but can dramatically expand access for people who previously had nothing.

That’s part of why Amano resonated so quickly. The story is easy to understand because the problem is already obvious to millions of people.

And from an investing perspective, those are usually the categories worth paying attention to early. Large markets, high friction, and products simple enough that adoption can spread organically if they work well enough.

Amano is still very early, and there are real questions around regulation, product quality, retention, and whether the technology holds up once the viral attention fades. But even this early, the company is pointing at something important.

A lot of healthcare categories are still weighed down by high costs, heavy friction, and systems that make basic access harder than it should be. Amano stands out because the company seems to be starting with accessibility first and building outward from there.

That doesn’t guarantee the product succeeds. However, it does make the company worth paying attention to. If Amano can build something that’s affordable, safe, and genuinely useful for even a portion of the people currently underserved by hearing care, the upside could end up being much larger than the current product price suggests.

As a reminder: We’re preparing for our first close and expect to begin deploying capital in June. The urgency is real. We already have a promising founder holding allocation for us in a company with rare early traction: a six-figure waitlist, millions of organic views, thousands of beta users, strong engagement, proprietary consumer data, and early pull from major media and entertainment players.

This is exactly why we’re moving now. The best early allocations don’t stay open forever.

If you’re an accredited investor interested in backing overlooked Muslim-origin and values-aligned founders before these rounds become obvious to the broader market, reply “Horizon” and we’ll send over the deck.

At Dhow, we look for companies rethinking markets that have stayed too expensive, complex, and inaccessible for too long.

Amano is interesting because the bet isn’t just better hearing technology. It’s that much of the friction around hearing care may not need to exist at all.

Most startups attacking broken markets won’t work. But the ones worth watching are usually the ones asking the simplest question first: why does this have to be so hard?

If that kind of thinking resonates, share this with someone who sees technology and healthcare the same way.

If you enjoyed this, you’d be doing us a HUGE FAVOR by just clicking the ads below - we appreciate it!

Talk through your reply and get polished, professional text ready to paste. Wispr Flow strips filler, fixes grammar, and formats everything. 89% sent with zero edits. Works everywhere.

Try Wispr Flow free

Those requests came from non-traded BDC investors in Q1 2026, and most got back roughly half of what they asked for. Moody's U.S. BDC sector outlook: Negative.

On Percent's marketplace that same quarter: new issuances, scheduled payments, 0.44% lifetime net loss rate on asset-based deals since inception.† The difference is structural: concentrated corporate loans with redemption windows that close at manager discretion vs. asset-based finance with 6–24 month deal terms. 14.6% net ABS returns LTM after losses (3/31/26).† Starting at $500.

See how private credit works when it's built for individual investors.

_{Alternative investments are speculative. No assurance can be given that investors will receive a return of their capital. †Past performance is not indicative of future results. Terms apply.}

Sources